Update on use of aldesleukin for treatment of high-risk metastatic melanoma

References

• CarbonePPCostelloWEastern Cooperative Oncology Group studies with DTIC (NSC-45388)Cancer Treat Rep1976602193198769973
   PubMedGoogle Scholar
• PatelPMSuciuSMortierLExtended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032)Eur J Cancer201147101476148321600759
   PubMed Web of Science ®Google Scholar
• DaviesHBignellGRCoxCMutations of the BRAF gene in human cancerNature2002417689294995412068308
   PubMed Web of Science ®Google Scholar
• ChapmanPBHauschildARobertCImproved survival with vemurafenib in melanoma with BRAF V600E mutationN Engl J Med2011364262507251621639808
   PubMed Web of Science ®Google Scholar
• HauschildAGrobJJDemidovLVDabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialLancet2012380983935836522735384
   PubMed Web of Science ®Google Scholar
• JohannessenCMBoehmJSKimSYCOT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature2010468732696897221107320
   PubMed Web of Science ®Google Scholar
• NazarianRShiHWangQMelanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature2010468732697397721107323
   PubMed Web of Science ®Google Scholar
• StraussmanRMorikawaTSheeKTumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretionNature2012487740850050422763439
   PubMed Web of Science ®Google Scholar
• MontagutCSharmaSVShiodaTElevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanomaCancer Res200868124853486118559533
   PubMed Web of Science ®Google Scholar
• EmeryCMVijayendranKGZipserMCMEK1 mutations confer resistance to MEK and B-RAF inhibitionProc Natl Acad Sci U S A200910648204112041619915144
   PubMed Web of Science ®Google Scholar
• WhittakerSRTheurillatJPVan AllenEA genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibitionCancer Discov20133335036223288408
   PubMed Web of Science ®Google Scholar
• ShiHMoriceauGKongXMelanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistanceNat Commun2012372422395615
   PubMed Web of Science ®Google Scholar
• PoulikakosPIPersaudYJanakiramanMRAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Nature2011480737738739022113612
   PubMed Web of Science ®Google Scholar
• FlahertyLEOthusMAtkinsMBSouthwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma – an Intergroup Study of cancer and leukemia Group B, Children’s Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology GroupJ Clin Oncol201432333771377825332243
   PubMed Web of Science ®Google Scholar
• PardollDMThe blockade of immune checkpoints in cancer immunotherapyNat Rev Cancer201212425226422437870
   PubMed Web of Science ®Google Scholar
• PeggsKSQuezadaSAKormanAJAllisonJPPrinciples and use of anti-CTLA4 antibody in human cancer immunotherapyCurr Opin Immunol200618220621316464564
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med2011364262517252621639810
   PubMed Web of Science ®Google Scholar
• SchadendorfDHodiFSRobertCPooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanomaPaper presented at the European Cancer Congress (ECCO-ESMO-ESTRO)September 27 to October 1, 2013Amsterdam, The Netherlands
   Google Scholar
• HamidORobertCDaudASafety and tumor responses with lambrolizumab (anti-PD-1) in melanomaN Engl J Med2013369213414423724846
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• RobertCLongGVBradyBNivolumab in previously untreated melanoma without BRAF mutationN Engl J Med2015372432033025399552
   PubMed Web of Science ®Google Scholar
• WolchokJDKlugerHCallahanMKNivolumab plus ipilimumab in advanced melanomaN Engl J Med2013369212213323724867
   PubMed Web of Science ®Google Scholar
• BoymanOSprentJThe role of interleukin-2 during homeostasis and activation of the immune systemNat Rev Immunol201212318019022343569
   PubMed Web of Science ®Google Scholar
• MinamiYKonoTMiyazakiTTaniguchiTThe IL-2 receptor complex: its structure, function, and target genesAnnu Rev Immunol1993112452688476561
   PubMed Web of Science ®Google Scholar
• GaffenSLSignaling domains of the interleukin 2 receptorCytokine2001142637711356007
   PubMed Web of Science ®Google Scholar
• SugamuraKTakeshitaTAsaoHThe IL-2/IL-2 receptor system: involvement of a novel receptor subunit, gamma chain, in growth signal transductionTohoku J Exp Med199216822312371306308
   PubMed Web of Science ®Google Scholar
• LordJDMcIntoshBCGreenbergPDNelsonBHThe IL-2 receptor promotes proliferation, bcl-2 and bcl-x induction, but not cell viability through the adapter molecule ShcJ Immunol19981619462746339794391
   PubMed Web of Science ®Google Scholar
• FriedmannMCMigoneTSRussellSMLeonardWJDifferent interleukin 2 receptor beta-chain tyrosines couple to at least two signaling pathways and synergistically mediate interleukin 2-induced proliferationProc Natl Acad Sci USA1996935207720828700888
   PubMed Web of Science ®Google Scholar
• ChengGYuAMalekTRT-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cellsImmunol Rev20112411637621488890
   PubMed Web of Science ®Google Scholar
• YuAZhuLAltmanNHMalekTRA low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cellsImmunity200930220421719185518
   PubMed Web of Science ®Google Scholar
• MartinsGACimminoLLiaoJMagnusdottirECalameKBlimp-1 directly represses Il2 and the Il2 activator Fos, attenuating T cell proliferation and survivalJ Exp Med200820591959196518725523
   PubMed Web of Science ®Google Scholar
• WeissGRGroshWWChianese-BullockKAMolecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanomaClin Cancer Res201117237440745021976537
   PubMed Web of Science ®Google Scholar
• JanasMLGrovesPKienzleNKelsoAIL-2 regulates perforin and granzyme gene expression in CD8+ T cells independently of its effects on survival and proliferationJ Immunol2005175128003801016339537
   PubMed Web of Science ®Google Scholar
• TsungKMekoJBPeplinskiGRTsungYLNortonJAIL-12 induces T helper 1-directed antitumor responseJ Immunol19971587335933659120294
   PubMed Web of Science ®Google Scholar
• PanelliMCWangEPhanGGene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administrationGenome Biol200237RESEARCH003512184809
   PubMed Web of Science ®Google Scholar
• de la RosaMRutzSDorningerHScheffoldAInterleukin-2 is essential for CD4+CD25+ regulatory T cell functionEur J Immunol20043492480248815307180
   PubMed Web of Science ®Google Scholar
• SadlackBLohlerJSchorleHGeneralized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cellsEur J Immunol19952511305330597489743
   PubMed Web of Science ®Google Scholar
• GattinoniLFinkelsteinSEKlebanoffCARemoval of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cellsJ Exp Med2005202790791216203864
   PubMed Web of Science ®Google Scholar
• RefaeliYVan ParijsLLondonCATschoppJAbbasAKBiochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosisImmunity1998856156239620682
   PubMed Web of Science ®Google Scholar
• KonradMWHemstreetGHershEMPharmacokinetics of recombinant interleukin 2 in humansCancer Res1990507200920172317789
   PubMed Web of Science ®Google Scholar
• AtkinsMBLotzeMTDutcherJPHigh-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993J Clin Oncol19991772105211610561265
   PubMed Web of Science ®Google Scholar
• SchwartzentruberDJGuidelines for the safe administration of high-dose interleukin-2J Immunother200124428729311565830
   PubMed Web of Science ®Google Scholar
• SasseADSasseECClarkLGUlloaLClarkOAChemoimmunotherapy versus chemotherapy for metastatic malignant melanomaCochrane Database Syst Rev20071CD00541317253556
   PubMed Web of Science ®Google Scholar
• IvesNJStoweRLLoriganPWheatleyKChemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patientsJ Clin Oncol200725345426543418048825
   PubMed Web of Science ®Google Scholar
• BedikianAYJohnsonMMWarnekeCLSystemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survivalJ Immunotoxicol20085220120718569391
   PubMed Web of Science ®Google Scholar
• SchwartzentruberDJLawsonDHRichardsJMgp100 peptide vaccine and interleukin-2 in patients with advanced melanomaN Engl J Med2011364222119212721631324
   PubMed Web of Science ®Google Scholar
• RosenbergSAYangJCSherryRMDurable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapyClin Cancer Res201117134550455721498393
   PubMed Web of Science ®Google Scholar
• RadvanyiLGBernatchezCZhangMSpecific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patientsClin Cancer Res201218246758677023032743
   PubMed Web of Science ®Google Scholar
• BesserMJShapira-FrommerRItzhakiOAdoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapiesClin Cancer Res201319174792480023690483
   PubMed Web of Science ®Google Scholar
• DudleyMEWunderlichJRYangJCA phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanomaJ Immunother200225324325112000866
   PubMed Web of Science ®Google Scholar
• YeeCThompsonJAByrdDAdoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cellsProc Natl Acad Sci U S A20029925161681617312427970
   PubMed Web of Science ®Google Scholar
• EllebaekEIversenTZJunkerNAdoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose interleukin-2 in metastatic melanoma patientsJ Transl Med20121016922909342
   PubMed Web of Science ®Google Scholar
• KaufmanHLKirkwoodJMHodiFSThe society for immunotherapy of cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanomaNat Rev Clin Oncol2013101058859823982524
   PubMed Web of Science ®Google Scholar